You are here

Share:

Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use

Primary tabs

View PDF
Summary
Researchers at the NCI seek licensing and/or co-development research collaborations for an anti-viral polypeptide, Griffithsin, and its antiviral use against Hepatitis C, Severe Acute Respiratory Syndrome (SARS), H5N1, or Ebola.
NIH Reference Number
E-025-2006
Product Type
  • Therapeutics
Keywords
  • Griffithsin, anti-viral, influenza, Corona virus, SARS, Ebola, O’Keefe
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003).  Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection. 

Issued patents: US 8,088,729 (Jan. 3, 2012) and foreign rights in France, Germany, Ireland, United Kingdom, Switzerland (all granted)

Potential Commercial Applications
  • Microbicide that can prevent viral transmission
  • Therapeutic against enveloped virus-mediated diseases 
Competitive Advantages
  • Highly Potent Broad-Spectrum Antiviral Lectin
  • Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.
Inventor(s)

Barry R. OKeefe (NCI), James McMahon, Toshiyuki Mori (NCI)

Development Stage
  • Discovery (Lead Identification)
Publications

Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. [PMID 15613479]

Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture [PMID: 16300962]

Patent Status
  • U.S. Patent Issued: U.S. Patent Number 8,088,729, Issued 03 Jan 2012
Related Technologies
Therapeutic Area
  • Infectious Diseases
Posted
Wednesday, July 7, 2021